Vanda Pharmaceuticals Inc. (VNDA)
| Market Cap | 241.25M -25.8% |
| Revenue (ttm) | 215.72M +6.0% |
| Net Income | -274.85M |
| EPS | -4.63 |
| Shares Out | 60.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,857,169 |
| Open | 4.040 |
| Previous Close | 3.940 |
| Day's Range | 3.880 - 4.110 |
| 52-Week Range | 3.875 - 9.940 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+188.22%) |
| Earnings Date | Oct 28, 2026 |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop... [Read more]
Financial Performance
In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 188.22% from the latest price.
News
Vanda Pharmaceuticals announces results from Study 3601
Vanda Pharmaceuticals (VNDA) announced results from Study 3601, a Phase III randomized, placebo-controlled study evaluating Nereus, an oral neurokinin-1, or NK-1, receptor antagonist, for the preventi...
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% ...
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on ...
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder failed the main goal of a late-stage study, prompting the company to put the program on hold pending further...
Vanda Pharmaceuticals: Phase 3 study of VQW-765 did not meet primary endpoint
Vanda Pharmaceuticals (VNDA) provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor partial agonist. Vanda’s Phase III clin...
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 202...
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being hel...
Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ
Vanda Pharmaceuticals (VNDA) announced positive topline results from its pivotal Phase III study of HETLIOZ, or tasimelteon, 20 mg in adults with Delayed Sleep-Wake Phase Disorder, or DSWPD. Vanda int...
Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint
In after-hours trading, shares are up 33% to $6.69.
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ ® treated participants shifted sleep at least 30 minutes earlier, compared to...
Vanda Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of Vanda Pharmaceuticals (VNDA) with an Outperform rating and $10 price target Fanapt is benefiting from strong bipolar I disorder adoption, while B...
Vanda Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Five approved products anchor a diversified portfolio, with BYSANTI and NEREUS launches driving near-term growth. Key clinical readouts for MDD and GLP-1-induced nausea could unlock major new markets, while commercial infrastructure is primed for expansion.
Vanda Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Two new drugs, NEREUS and BYSANTI, have been approved, with BYSANTI's launch and a major switch strategy from Fanapt expected to drive near-term revenue. Multiple phase III readouts and a focus on product diversification support a $750 million psychiatry revenue target by 2030.
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in Septembe...
Vanda awarded Orphan Designation in Europe for treatment of GPP
Vanda Pharmaceuticals (VNDA) announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European ...
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European ...
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher...
Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
B. Riley lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $12 from $17 and keeps a Buy rating on the shares. Vanda’s Q2 revenue miss was largely timing-related,…
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $21 and keeps a Buy rating on the shares. The company reported a revenue and earnings…
Vanda Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw strong Fanapt growth and early NEREUS launch, offset by HETLIOZ declines from generic competition. Revenue guidance for 2026 is $240M–$290M, with operating expenses expected to moderate by late 2026 and cash resources sufficient through 2027.
Vanda Pharmaceuticals Earnings release: Q2 2026
Vanda Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Vanda Pharmaceuticals Quarterly report: Q2 2026
Vanda Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
Reports Q2 revenue $50.53M vs. $52.59M last year. “We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to…
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
16:03 EDT Vanda Pharmaceuticals (VNDA) sees FY26 revenue $240M-$290M, consensus $262.1M
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% Full-year 2026 total revenue guidance of $240-$290 million Cash totaled $170.0 million as of June ...